Tonix Pharmaceuticals Holding CorpTNXP
Price$9.74

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $29.1M+188.3% YoYTTM through 30 Jun 2026
Net Income -$159.7MTTM through 30 Jun 2026
Free Cash Flow -$158.1MTTM through 30 Jun 2026

Margins

Current
Gross Margin77.1%
EBITDA Margin-561.1%
Operating Margin-627.0%
Net Margin-548.6%

Returns

-64.9%ROE
-15.6%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio6.99x
Net Debt-$185.5Mnet cash position
Cash & Equivalents$176.2M

Quality Metrics

Altman Z-Score-2.95
Piotroski F-Score2 / 9
FCF Margin-543.3%
Rule of 40-525.8
Earnings-Beat Rate0.0%

Multi-Year Trend

Revenue
'23'24'25
FY2025: $13.1M
Diluted EPS-$13.09TTM
'21'22'23'24'25
FY2025: $-14.57

Dividend

No dividend

Capital Allocation

Capex Intensity17.6%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.